Venture capital

BT Catalyst, July-August, 2005

Tranzyme Pharma of Research Triangle Park has raised $32 million in private .nancing led by H.I.G. Ventures; Thomas, McNerney & Partners; and Quaker BioVentures. Additional participants in the round included existing investors, Business Development Bank of Canada (BDC Venture Capital), Desjardins Venture Capital, Pacific Rim Ventures and The Solidarity Fund (FTQ).

Voyager Pharmaceuticals of Raleigh completed a $10 million equity placement, mostly purchased by Voyager's existing shareholders.

Biopheresis Technologies of Cary has secured $8 million in Series A financing from European investors including Scandinavian Life Science Venture of Stockholm and First Ventury of Heidelberg, Germany.

Aeolus Pharmaceuticals of Research Triangle Park has secured up to $2.5 million in new funding from existing investors, including Xmark Opportunity Funds and the Biotechnology Value Fund LP, in the form of convertible preferred stock and warrants.